tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Shihab FS et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. 2008 Transplantation pmid:18475181
Ekberg H Calcineurin inhibitor sparing in renal transplantation. 2008 Transplantation pmid:18813097
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Fischer L et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. 2015 Transplantation pmid:26151607
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Abbott KC et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. 2005 Transplantation pmid:16340779
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Luan FL et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. 2002 Transplantation pmid:12042641
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Kiuchi T CNIs: immediate benefits but storing problems for the future? 2008 Transplantation pmid:18946338
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Chisholm MA et al. Coadministration of tacrolimus with anti-acid drugs. 2003 Transplantation pmid:12973105
Koch R et al. Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. 2003 Transplantation pmid:12973123
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Opelz G and Döhler B Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. 2008 Transplantation pmid:18698238
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Pascual J et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. 2010 Transplantation pmid:20335831
Raggi MC et al. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. 2010 Transplantation pmid:21076373
Sahara H et al. Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. 2010 Transplantation pmid:21076382
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Gruber SA and Doshi MD Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. 2010 Transplantation pmid:20440195
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Wong W et al. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? 2005 Transplantation pmid:16082321
Krämer BK et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. 2012 Transplantation pmid:22858806
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110